Johnson and Johnson’s one-dose vaccine “appears to be safe and effective.”
The National Institutes of Health within the U.S. Health and Human Services Department has announced that “investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data.”
Johnson & Johnson took longer than their counterparts in developing a COVID-19 vaccine, but the study released Friday showed one dose to be effective against up to 85% of severe COVID-19 symptoms. Another benefit of the new vaccine is that it can be kept in refrigeration storage rather than frozen, decreasing the possibility of spoilage. J&J is seeking emergency authorization to administer the vaccine in the U.S.
As the Lord Leads, Pray with Us…
- For the United States as the hope of the end of the pandemic nears.
- For the FDA in their considerations as J&J seek emergency authorization.
- For researchers and scientists as they continue to develop treatments and mitigations for disease.
Sources: AP, NIH.gov
